Encompass Health (NYSE:EHC) Releases FY24 Earnings Guidance

Encompass Health (NYSE:EHC) issued an update on its FY24 earnings guidance on Wednesday morning. The company provided earnings per share (EPS) guidance of $3.86-4.11 for the period, compared to the consensus estimate of $3.98. The company issued revenue guidance of $5.250-5.325 billion, compared to the consensus revenue estimate of $5.25 billion.

Encompass Health Stock Performance

Shares of EHC stock traded up $0.26 during mid-day trading on Wednesday, reaching $82.72. The stock had a trading volume of 1,216,634 shares, compared to its average volume of 662,203. The business’s fifty day moving average is $77.89 and its 200-day moving average is $70.67. The company has a current ratio of 1.28, a quick ratio of 1.28 and a debt-to-equity ratio of 1.19. The firm has a market cap of $8.28 billion, a price-to-earnings ratio of 23.84, a PEG ratio of 1.49 and a beta of 0.94. Encompass Health has a 1-year low of $57.55 and a 1-year high of $83.73.

Encompass Health (NYSE:EHC) last announced its quarterly earnings data on Wednesday, February 7th. The company reported $0.95 earnings per share for the quarter, beating analysts’ consensus estimates of $0.83 by $0.12. The business had revenue of $1.25 billion for the quarter, compared to analyst estimates of $1.24 billion. Encompass Health had a return on equity of 17.69% and a net margin of 7.33%. On average, research analysts forecast that Encompass Health will post 3.96 earnings per share for the current year.

Encompass Health Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Monday, April 15th. Stockholders of record on Monday, April 1st were paid a $0.15 dividend. The ex-dividend date was Thursday, March 28th. This represents a $0.60 dividend on an annualized basis and a dividend yield of 0.73%. Encompass Health’s payout ratio is 17.29%.

Wall Street Analysts Forecast Growth

EHC has been the topic of a number of recent research reports. William Blair restated an outperform rating on shares of Encompass Health in a research note on Wednesday, February 7th. Truist Financial upped their target price on Encompass Health from $82.00 to $86.00 and gave the stock a buy rating in a research note on Friday, February 9th. Royal Bank of Canada reiterated an outperform rating and set a $83.00 price target on shares of Encompass Health in a research report on Friday, February 9th. Barclays increased their price target on Encompass Health from $95.00 to $101.00 and gave the stock an overweight rating in a research report on Thursday, March 28th. Finally, Mizuho increased their price target on Encompass Health from $77.00 to $82.00 and gave the stock a buy rating in a research report on Friday, February 9th. Eight equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Encompass Health presently has an average rating of Buy and an average target price of $83.22.

About Encompass Health

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.